Amit Gupta Sells 5,964 Shares of Cardlytics, Inc. (NASDAQ:CDLX) Stock

Cardlytics, Inc. (NASDAQ:CDLX) CEO Amit Gupta sold 5,964 shares of the firm’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $3.67, for a total transaction of $21,887.88. Following the completion of the transaction, the chief executive officer now directly owns 186,904 shares of the company’s stock, valued at approximately $685,937.68. This trade represents a 3.09 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Amit Gupta also recently made the following trade(s):

• On Thursday, October 24th, Amit Gupta sold 22,607 shares of Cardlytics stock. The stock was sold at an average price of $3.85, for a total transaction of $87,036.95.

Cardlytics Stock Performance

Cardlytics stock traded down $0.32 during midday trading on Monday, reaching $3.49. 2,033,344 shares of the company’s stock were exchanged, compared to its average volume of 1,212,448. The stock’s 50-day simple moving average is $3.93 and its 200 day simple moving average is $4.85. The firm has a market cap of $177.37 million, a price-to-earnings ratio of -0.57 and a beta of 1.53. The company has a debt-to-equity ratio of 2.40, a quick ratio of 1.18 and a current ratio of 1.18. Cardlytics, Inc. has a 52 week low of $2.89 and a 52 week high of $20.52.

Cardlytics (NASDAQ:CDLX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.18. The company had revenue of $67.06 million during the quarter, compared to analysts’ expectations of $57.77 million. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The business’s revenue was down 15.1% on a year-over-year basis. During the same period last year, the firm posted ($0.26) earnings per share. On average, analysts expect that Cardlytics, Inc. will post -1.52 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cardlytics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CDLX. RBF Capital LLC raised its position in shares of Cardlytics by 311.9% in the third quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock valued at $1,562,000 after purchasing an additional 369,620 shares during the period. GSA Capital Partners LLP grew its stake in Cardlytics by 1,273.2% in the 3rd quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock valued at $1,223,000 after buying an additional 354,474 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Cardlytics by 711.9% in the 2nd quarter. Renaissance Technologies LLC now owns 351,035 shares of the company’s stock valued at $2,882,000 after acquiring an additional 307,800 shares during the period. Jacobs Levy Equity Management Inc. lifted its position in Cardlytics by 56.0% during the third quarter. Jacobs Levy Equity Management Inc. now owns 317,644 shares of the company’s stock worth $1,016,000 after acquiring an additional 113,966 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Cardlytics by 7.5% during the third quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company’s stock worth $3,371,000 after acquiring an additional 73,484 shares during the period. 68.10% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

CDLX has been the topic of a number of recent research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Cardlytics in a research report on Thursday, November 7th. Evercore ISI initiated coverage on Cardlytics in a research note on Friday, October 11th. They issued an “in-line” rating and a $4.00 price target for the company. Finally, Craig Hallum upgraded Cardlytics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $6.92.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.